A link to the newly published ICMRA paper, which provides a valuable insight into how global regulators have managed regulatory oversight, inspections and assessments during the pandemic to support both the COVID-19 response, and also ‘business as usual’ GMP and GCP inspections.
In March of this year, a letter was sent to Manufacturer’s “Specials” (MS) Licence holders who were involved in the manufacture of sterile products. An overview of unlicenced medicines guidance is provided here: Supply unlicensed medicinal products (specials) This was …
The purpose of this blog is to describe our approach to the validity date of UK issued certificates confirming compliance with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). Following the end of the COVID-19 public health emergency declared …
Come and join the next MHRA Symposia in February 2025 and hear the latest on Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) in the UK from MHRA inspectors and regulators. Registration is available on the dedicated symposia website for in-person …
As a GCP Inspector at the UK Medicines and Healthcare products Regulatory Agency (MHRA), I thought it would be useful to inform you that Annex 2 of the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) Guideline has …
February 2025: We have updated some details in this blog post to reflect changes to the payment system and annual progress reports (APRs). The process for submitting Annual Safety Reports (ASRs) for Clinical Trials of Investigational Medicinal Products (CTIMP) to the …
The world of GPvP is highly regulated, but the 2024 GPvP symposium showcased how regulation, collaboration and innovation can work together to enhance compliance, provide opportunities for better ways of working, and improve patient lives. The Symposium welcomed over five …
Launch of a pilot Single Inspection Program, a global approach to GMP inspections of third country manufacturers. Health Canada, the Therapeutic Goods Administration (TGA) and the Medicines & Healthcare products Regulatory Agency (MHRA), all members of the Pharmaceutical Inspection Co-operation Scheme …
Join this unique one-day Symposium on 28 February 2024 and hear the latest on Good Pharmacovigilance Practice (GPvP) in the UK from MHRA inspectors and regulators. Registration is available on the GPvP Symposium website for in-person attendance in West London …
Amendments to the guidance on the MHRA website stipulating changes to the way updates to a MAH’s PV system should be notified to the MHRA have been published. The changes aim to make administration burden less for both MAHs and …
Following the end of the COVID-19 public health emergency declared by WHO in May 2023[1], on-site GMP and GDP inspections were restarted after being postponed or carried out remotely during the pandemic. A number of postponed inspections still need to …
